- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
- Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab)
- Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
- Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
- Alvotech streymir kynningu fyrir fjárfesta 3. apríl 2024 kl. 12:15 að íslenskum tíma
- Alvotech tilkynnir um útgáfu eigin hlutabréfa
- Alvotech Announces Increase in Number of Own Shares
More ▼
Key statistics
On Friday, Alvotech SA (ALVO:NMQ) closed at 14.15, -21.39% below its 52-week high of 18.00, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.00 |
---|---|
High | 14.23 |
Low | 14.00 |
Bid | 12.52 |
Offer | 14.28 |
Previous close | 13.65 |
Average volume | 349.82k |
---|---|
Shares outstanding | 266.82m |
Free float | 72.67m |
P/E (TTM) | -- |
Market cap | 3.64bn USD |
EPS (TTM) | -2.40 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼